Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome - Full Text View

Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome

This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), March 2008

Sponsors and Collaborators:	NCI - Center for Cancer Research-Medical Oncology National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00075348

Purpose

RATIONALE: The identification of gene mutations in individuals who have or are at risk for von Hippel-Lindau syndrome may allow doctors to better determine the genetic processes involved in the development of cancer.

PURPOSE: This genetic study is finding gene mutations in participants with von Hippel-Lindau syndrome or who are at risk for developing von Hippel-Lindau syndrome.

Condition	Intervention
Kidney Cancer Von Hippel-Lindau Syndrome	Procedure: mutation analysis

Genetics Home Reference related topics:

von Hippel-Lindau syndrome

MedlinePlus related topics:

Cancer Kidney Cancer Von Hippel-Lindau Disease

U.S. FDA Resources

Study Type:	Observational

Official Title:	Genetic Mutation Analysis In A VHL Population

Further study details as provided by National Cancer Institute (NCI):

Estimated Enrollment:	260
Study Start Date:	December 2003

Detailed Description:

OBJECTIVES:

Obtain laboratory identification and confirmation of research results for gene mutations in participants previously enrolled in NCI-99-C-0053 who have von Hippel-Lindau (VHL) syndrome or who are at risk for VHL syndrome.
Determine genotype status in these participants.

OUTLINE: Participants submit a blood or buccal sample for genetic mutation analysis. Participants may receive genetic counseling and/or the results of genetic testing, if desired.

PROJECTED ACCRUAL: A maximum of 260 participants will be accrued for this study.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Prior enrollment in the von Hippel-Lindau (VHL) Syndrome Epidemiology Study NCI-99-C-0053
Meets 1 of the following criteria:
- Diagnosis of VHL syndrome
- At risk of VHL syndrome
- Family member of patient with VHL syndrome
VHL syndrome genotype is not known

PATIENT CHARACTERISTICS:

Age

Adult

Performance status

Not specified

Life expectancy

Not specified

Hematopoietic

Not specified

Hepatic

Not specified

Renal

Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy

Not specified

Chemotherapy

Not specified

Endocrine therapy

Not specified

Radiotherapy

Not specified

Surgery

Not specified

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00075348

Locations


United States, Maryland
	Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office	Recruiting
	Bethesda, Maryland, United States, 20892-1182
	Contact: Patient Recruitment 888-NCI-1937

Sponsors and Collaborators

NCI - Center for Cancer Research-Medical Oncology

National Cancer Institute (NCI)

Investigators


Study Chair:	William M. Linehan, MD	NCI - Urologic Oncology Branch

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Study ID Numbers:	CDR0000302478, NCI-03-C-0148
First Received:	January 9, 2004
Last Updated:	October 18, 2008
ClinicalTrials.gov Identifier:	NCT00075348
Health Authority:	Unspecified

Keywords provided by National Cancer Institute (NCI):

renal cell carcinoma

von Hippel-Lindau syndrome

Study placed in the following topic categories:

Angiomatosis

Von Hippel-Lindau syndrome

Vascular Diseases

Urogenital Neoplasms

Renal cancer

Kidney cancer

Urologic Neoplasms

Carcinoma

Von Hippel-Lindau Disease

Urologic Diseases

Kidney Neoplasms

Carcinoma, Renal Cell

Kidney Diseases

Adenocarcinoma

Urinary tract neoplasm

Neoplasms, Glandular and Epithelial

Neurocutaneous Syndromes

Additional relevant MeSH terms:

Neoplasms

Pathologic Processes

Disease

Neoplasms by Site

Neoplasms by Histologic Type

Syndrome

Nervous System Diseases

Cardiovascular Diseases

ClinicalTrials.gov processed this record on November 20, 2008